Skip to navigation Skip to main content

ONIVYDE (liposomal irinotecan) for Pancreatic Cancer

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for ONIVYDE (liposomal irinotecan), indicated for pancreatic cancer.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 11: Clinical Pharmacology
Slide 16: Warnings and Precautions
Slide 20: Clinical Safety and Efficacy
Slide 27: Drug Storage and Supply
Slide 30: References

Topics:

Drug Showcase Pancreatic Cancer
  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More